Activity against human immunodeficiency virus (HIV) in the, naphthalenesulphonic acid series is most pronounced in the disulphonic acid series. In this class of compounds, N-acyl derivatives of 4-amino-5-hydroxy-2,7-naphtha1enedisulphonic acid demonstrate significant anti-HIV activity at non-toxic doses. The most potent compounds in this group of agents are bis naphthalenedisulphonic acids. A bis derivative containing a decamethylene spacer demonstrated activity against HIV-1, HIV-2 giant cell formation and reverse transcriptase (RT). This compound also demonstrated an in vitro therapeutic index (ratio of 50% cytotoxic concentration to 50% inhibitory antiviral concentration) of 10.6. Molecular modelling analyses of this agent, suramin, and several suramin analogues were undertaken to explain the potent anti-HIV-1 RT activity. These studies were carried out using the molecular decomposition/recomposition strategy, conformational searching, energy minimization and molecular dynamics (MOl simulation. The bis naphthalenedisulphonic acid derivative compound 1, having a flexible decamethylene spacer, was shown to be able to mimic the helical twist of the B-ONA backbone as a low energy conformer state.
Introduction
The discovery of a retrovirus (Barre-Sinoussi et al., 1983; Gallo et st., 1984) as the causative agent of acquired immunodeficiency syndrome (AIDS) has rejuvenated interest in antiretroviral therapy. Presently, only 3'-azido-2',3'-dideoxythymidine (AZl) is licensed for wide-scale use and is known to prolong survival in AIDS patients (Hirsch, 1988) . With the advent of AZT, the search for other nucleoside analogues of anti-human immunodeficiency virus (HIV) agents has intensified (De Clercq, 1989a) . AZT, like many of the other active nucleoside agents, is a chain terminator and a reverse transcriptase (Rl) inhibitor (Yarchoan and Broder, 1989) . However, AZT use has been accompanied by bone marrow suppression (Richman et al., 1987) , resumption of viral replication during therapy (Reiss et al., 1988) , the occurrence of cell to cell virus transmission during treatment (Gupta et al., 1989) , and the emergence of AZT-resistant HIV-1 strains during prolonged therapy (Larder et aI., 1989) .
The above facts have provided the impetus to search for other sources to provide new anti-HIV agents. A wide variety of compounds with diverse chemical structures has shown inhibitory activity against HIV. Many of these agents have exhibited mechanisms of action involving RT inhibition and/or other molecular targets. Amongst these derivatives are natural products and analogues, and many other chemical entities (DeClercq, 1989a,b) . However, the long-term usefulness of these agents as anti-AIDS therapies remains to be ascertained. Therefore, there still remains a need for the rational design and evaluation of new potential drug candidates as modalities to treat AIDS.
In our continuing search for new non-nucleoside anti-AIDS leads, we have been investigating the naphthalenesuiphonic acids (Mohan et al., 1990a,b) . Previous work in these laboratories have revealed potent and selective antiviral activity in bis naphthalenedisulphonic acid derivatives against both HIV-1 and HIV-2 (Mohan et aI., 1991a,b) . In this report we analyse the potent activity of a bis naphthalenedisulphonic acid against HIV-1 RT by using molecular modelling techniques.
Results
Compound 1 displayed significant anti-HIV activity, as measured by several assays (Tables 1-3 ). In the purified recombinant HIV-1 RTassay, compound 1 [50% inhibitory concentration (ICso) = 2.8 tLM], a derivative of 4-amino-5hydroxy-2,7-naphthalenedisulphonic acid with a flexible decamethylene spacer, was almost as potent as suramin Table 2 . Inhibitory effects of compound 1 and suramin onHIV-induced cy1opathogenicity in MT-4 and MOLT-4 cells. Fig. tc, The superposition of (1) in the charged form to B-DNA using S to P atom-pair matching did not give a well-defined fit because there are only four sulphur atoms to drive the fit. Superposition of (1) in its neutral minimum energy conformation to B-DNA was not as good as the charged form because (1) shrinks in length in the neutral form.
We carried out a conformational analysis of suramin as well. The lowest energy helical structure on the MD trajectory is shown in Fig. 2a . The superposition of the helical conformation of suramin on the sugar phosphate backbone of B-form DNA (Fig. 1b) is shown in Fig. 2b . All the other helices could be generated from small torsion angles excursions from this structure. Neutralization of the suiphonic acid groups decreased the relative stability of the helix, and the helix modestly shrank in length but retained the dominant features of the charged conformer state.
'{Vealso assigned the helical conformation of suramin to one of its analogues, compound 2, which was shown by other workers to be active against HIV-1 RT activity [ID so = 12 [L/ml (10.9 [LM)] and displays toxicity to host cells at 500 [Lg/ml (455 [LM) (Jentsch et al., 1987) . MD simulations indicated that the helical conformation of suramin was also the stable conformation for (2). However, only one of the two sodium paracarbonylaminobenzenesulphonate groups on each end of the molecule participated in the helical conformation at any given time. The other group on each end of the molecule stuck out into a space not occupied by any groups on suramin. Thus, the lower toxicity of compound 2 might be due to the steric bulk of these groups interfering with binding to polymerases. These groups apparently can be tolerated by RT, and, in fact, may mediate binding since compound 2 is reported to be more active than suramin (Jentsch et el., 1987) . MD studies on compound 3 carried out in the same manner as for compound 2 indicated that the ends of this 2.8 1.6
Ic 50 a (I-'M) a 50% antiviral effective concentration, based on the inhibition of HIVinduced cy1opathogenicity. b 50% cytotoxic concentration, based on the reduction of viability of mock-infected cells. c Disodium salt. Alldata represent mean values forat least twoseparate. experiments.
(IC so = 1.6 [LM) (fable 1). Compound 1 showed activity at doses that are non-toxic to host cells (fable 2). In MT-4 cells, the in vitro therapeutic index [ratio of 50% cytotoxic concentration (CC so) to IC so, Table 2 ] of compound 1 was 10.6. Potent activity was also demonstrated in the giant cell formation assay (Mohan et sl., 1991 b) .
We found that most of the molecular dynamic (MD) relaxation simulations of the active sulphonic acid derivatives converged to a common conformational family that mimicked a single sugar phosphate backbone of B-form DNA. The balance of the simulations remained stuck in relatively high-energy conformational minima. The global minimum energy family of conformations comprised structurally similar helices.
By way of example, the lowest energy helical structure on the MD trajectory for the charged form of compound 1 is shown in Fig. 1 . All the other helices could be generated from small torsion angles excursions from this structure. Neutralization of the suiphonic acid groups decreased the relative stability of the helix, and the helix modestly shrank in length but retained the dominant features of the charged conformer state.
Molecular superposition of the global energy minimum of the charged form of 1 ( Fig. 1a ) on the sugar phosphate backbone chain of B-form DNA (Fig. 1b) , by maximizing the common overlap steric volume, suggested that (1) has a very similar helical conformation to B-form DNA. The molecular superposition of (1) on B-form DNA is shown in molecule do not maintain a helical conformation, but are sharply 'bent'. This bending is due to sulphonate groups in the altho positions relative to the amide unit linkages. Torsion angle states about bonds in the amide units needed to sustain the helical conformation are sterically prohibited. Thus, the low RT inhibition activity (anti-Rl) of (3) [lD 50 = 190 p.g/ml (169 P.M)] and low toxicity at 500 p.g/ml (445p.M) (Jentsch et aI., 1987) may be due to the loss of the 'requisite' helical conformation.
Discussion
Suiphonic acid derivatives have played a pivotal role in anti-AIDS drug development. Suramin, a hexasulphonic acid derivative, was the first mode of therapy for AIDS (De Clercq, 1987) . Having being used as an antitrypanosomial agent for over 50 years, suramin was also shown to be a potent RT inhibitor (De Clercq, 1979) . However, suramin has not been pursued further for AIDS due to its clinical ineffectiveness and the appearance of considerable toxicity (Kaplan et a/., 1987) . On the other hand, on chemical and biological grounds, suramin remains a compound of potential therapeutic utility. For example, suramin has shown inhibition of protein kinase C (Mahoney et aI., 1990) and there is a renewed interest in suramin for the treatment of cancer (Stein et aI., 1989) . Suramin exhibits a half-life of 44-54 days, amongst the longest for a therapeutic drug. Although suramin seems to be a molecule that would be easily catabolized, it is remarkably resistant to metabolism in vivo (Collins et el., 1986) .
It may be argued that the long half-life of suramin, due to its strong protein binding property (Collins et a/., 1986) , may also be a contributing factor to its toxicity. On the other hand, a long half-life may be beneficial from a therapeutic stand-point. In this context, AlT has a half-life of approximately 1 h (Hirsch, 1988) , necessitating roundthe-clock administration. Interestingly, evaluation of fragments of suramin has shown that, unlike suramin, these fragments are easily eliminated from the blood (Spinks, 1948) . One anti-HIV study has shown that out of 90 suramin analogues, including some used in our modelling studies, 57 had activity, 24 of which were superior to suramin (Jentsch et a/., 1987) . These and other studies (Mohan et a/., 1990a (Mohan et a/., ,b, 1991a clearly demonstrate the anti-HIV potential in sulphonic acid derivatives. In this same group of compounds, Fuchsin acid, a sulphonic acid dye (Baba et el., 1988) , belonging to a chemical class different to the anti-HIV dyes (Balzarini et al., 1986) , has also demonstrated anti-HIVactivity. Two natural products containing suiphonic acid (Suzuki et aI., 1989; Gustafson et fil., 1989) have shown anti-HIV activity.
Adikesavalu and Camerman (196th National American Chemical Society Meeting, Los Angeles, CA, Sept. [25] [26] [27] [28] [29] [30] 1988 ) observed a helical conformation for suramin in the crystalline state. A comparison of crystal conformation of suramin to the sugar-phosphate backbone geometry of a single B-form DNA chain indicated a high degree of shape similarity and charge-in space matching. This has led these workers to postulate that suramin may exhibit one, or more, of its biological actions by acting as a structural DNA chain substitute.
At this time it is not clear how similar the crystal structure and calculated conformations of suramin are to one another. The crystal structure (Adikesavalu and Camerman, 196th National Chemical Society Meeting, 1988) is not a symmetric structure, while the computed conformations are symmetric, reflecting the symmetric chemical structure of suramin with respect to the urea (-NHCONH-) group. Most striking, however, is that the computed helical conformations are quite similar in shape to the backbone geometry of a single B-form DNA chain. This suggests, in agreement with Camerman's model (Adikesavalu and Camerman, 196th National American Chemical Society Meeting, 1988) , that suramin may inhibit RTby mimicking sugar phosphate backbone structures of polynucleotides. However, if suramin can mimic a DNA backbone structure, then it may also act as an inhibitor of cellular DNA polymerases, also in agreement with Carnerman's model. This inhibition is known (Basu and Modak, 1985) for suramin and may be a source of suramin's toxicity.
The structures of compounds 1-3 contain four sulphonic acid groups each. All the molecules have symmetrical structures. Compound 1 has two sulphonic acid groups on each terminal naphthalene moiety, while (2) and (3) have one and two sulphonic acid functionalities on terminal phenyl moieties, respectively. The chemical inhibition of RT by compound 1 may also be due to its bifunctional chelating potential (Mohan et aI., 1991a) with magnesium, a divalent cation required forthe optimum activity of HIV-1 RT (Hoffman et aI., 1985) . However, the lack of chelating ability, as exhibited by suramin, (2) anti-HIV activity at subtoxic doses, indicating the probable role of the suiphonic acid groups. The polar nature of these molecules may make it difficult to allow their entry into the virus-infected cells for interaction with RT.Although endocytosis may be suggested (De Clercq, 1987) , and literature evidence exists for cellular entry of sulphated derivatives (Ehlers and Diringer, 1984; Ishihara et al. 1986 ), these studies provide the impetus to design pro-drugs if viral entry of these molecules is required but not achieved.
Materials and Experimental procedures

Chemicals
Compound 1 was synthesized by reacting the respective naphthalenedisulphonic acid with the diacyl chloride in refluxing pyridine. After workup, the compound was purified and characterized by thin-layer chromatography (TLC), infrared (lR), nuclear magnetic resonance (NMR), mass spectrometry (MS) and elemental analyses, as described previously (Mohan et al., 1991a) . Procedures for (2) and (3) have been reported elswhere (Jentsch et al., 1987) . Suramin was purchased from Bayer AG., Wuppertal, Germany.
Assays for HIV inhibition
Antiviral assays. Activity of the compounds againstthe replication of HIV-1 and HIV-2 was based on the inhibition of virus-induced cytopathogenicity in MT-4 and MOLT-4 cells, as described previously (Pauwels et al., 1987) . Briefly, MT-4 and MOLT-4 cells were suspended in culture medium at 1 x 10 5 cells/ml and infected with HIV at a multiplicity of infection (MOl) of 0.02 and 0.2, respectively. Immediately after virus infection, 100 ILl of the cell suspension were brought into each well of a microtitre tray containing various concentrations of the test compounds. After a 4-day incubation period at 37"C, MOLT-4 cells were subcultured at a ratio of 1: 5 with fresh culture medium, containing appropriate concentrations of the compounds, and incubated further. The number of viable MT-4 and MOLT-4 cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTI) method Giant cell formation assays. The assay procedure for giant cell formation has been described previously (Baba et aI., 1990) . MOLT-4 cells were cultured with an equal number-of MOLT-4/ HTLV-III!3 for 24h, and the number of giant cells was determined microscopically.
RTassay. Purified recombinant HIV-1 RT (930 Ulml) was used in the assay. The assay was performed at 37"C for 30 min with 50 fLl reaction mixture containing 50mM Tris-HCI (pH 8.4), 2mM dithiothreitol, 100mMKCI, 10 mMMgCI 2 , 0.1% Triton X-100, 1 fLCi [methyl3HjdTIP (30 Ci/mmol), 0.01 U poly(Ra).oligo(Dt), test compound, and 0.01 U enzyme. The reaction was quenched with 200fLi of 5% trichloroacetic acid, and the precipitated material was analysed for radioactivity. The inhibitory effect of the compounds on HIV-1 RT was carried out according to the previously described protocol (Mohan et al., 1991b) .
Molecular modelling analyses
Conformational analyses of the sulphonic acid derivatives 1-3 and suramin (Fig. 3) were performed using the molecular decomposition/recomposition strategy (Hopfinger et al., 1984) , conformational searching (Orchard et al., 1987) , energy minimization (Orchard et aI., 1987) and MD (Weiner et al., 1984) . These methods were used by way of example for suramin, as follows: the initial set of trial torsion angle states was determined by finding the energy minima for each of the following decomposed substructures (Fig. 4) , which uniquely define suramin, using the fixed valence geometry approximation and systemic conformational searching of the indicated torsion angles at 30°r esolution (Pearlstein et al., 1988) .
The combinatorial set of minimum energy torsion angle states from (A), (B)and (C)were then used as starting points in the energy minimization of the total structure of (1). Those energy minima, within 10 kcal/mole of the apparent global minimum energy conformation, were retained as starting structures in MD simulations. An extended Amber force field (Weiner et el., 1984) ,
(B) (e)
available in the CHEMLAB-II molecular modelling package (Pearlstein et aI., 1988), using CNDO/2 partial atomic charges (PopIe and Beveridge, 1970) , was employed for all conformational search and energy minimization calculations. Both charged and neutral sulphonic forms of the molecules have been considered. The molecular dielectric was fixed at 3.5. The MOLSIM (Doherty and Hopfinger, 1989) package was used for the MD simulations. The MD simulations also used the same force field as the search and minimization studies. The MD simulations were performed for 30 ps at 300 0K and loosely coupled to a constant temperature bath. Molecular shape comparisons to the sugar phosphate backbone of a single chain of B-form DNA were performed according to the following two criteria: (i) maximizing the common overlap steric volume (Burke and Hopfinger, 1990 ) between the two molecules as a function of intermolecular geometry, and (ii) minimizing the sum of the squares of the distances between matched pairs of sulphurs and DNA phosphate groups.
